Tirzepatide Birth Control Interaction: What the Label Says

Tirzepatide birth control concerns are real but narrow. The FDA labels for Mounjaro and Zepbound say tirzepatide may reduce the efficacy of oral hormonal contraceptives because it slows how fast the stomach empties (FDA Mounjaro label, 2025). Contraceptives not taken by mouth should not be affected. The delay is largest after the first dose and fades over time. Semaglutide studies have not shown the same drop in hormone levels.

Key takeaways

• The FDA labels for Mounjaro and Zepbound say tirzepatide may reduce the efficacy of oral hormonal contraceptives, and that hormonal contraceptives not taken by mouth should not be affected.
• In the manufacturer's study, a single tirzepatide dose timed to its peak effect cut peak pill-hormone levels by 55% to 66% and total exposure by 20% to 23%.
• That study measured hormone blood levels in healthy volunteers, not pregnancies, so "may reduce" is the honest description.
• Semaglutide studies did not show a meaningful drop, but they used different designs and do not compare the two drugs head to head.
• Contraception, pregnancy plans and every oral medication you take belong in a GLP-1 intake, and a licensed clinician screens for reasons not to use tirzepatide at all.

What the tirzepatide birth control warning actually says

The US labels say tirzepatide may reduce how well birth control pills work because it delays gastric emptying. They advise people on oral contraceptives to switch to a non-oral method or add a barrier method after starting tirzepatide and after each dose increase (FDA Mounjaro label, 2025).

The label makes three separate points:

• General interaction. Tirzepatide delays gastric emptying and may affect absorption of oral medications taken at the same time. The label asks for monitoring of oral drugs that depend on reaching a threshold level or have a narrow therapeutic index, meaning a small gap between an effective level and a harmful one. Warfarin is its example.
• Contraception. Oral hormonal contraceptives may work less well. Hormonal contraceptives that are not taken by mouth should not be affected. The Zepbound label carries the same advice (Zepbound label, DailyMed).
• Patient wording. The Medication Guide says birth control pills taken by mouth may not work as well and tells patients to talk to a healthcare provider about suitable methods.

"May reduce" does not mean "will fail." The study behind the warning measured how much hormone reached the bloodstream and when. It did not count pregnancies. Lower hormone levels are a fair reason for caution, and how that applies to you is a decision for your clinician.

One disclosure before the details. New Blue's tirzepatide pathway uses compounded tirzepatide, and compounded medications are not FDA-approved. It has the same active ingredient as Mounjaro and Zepbound, which are FDA-approved brand products, but it is not equivalent to them or a generic of them. Every label statement and study result in this article comes from the brand products. The compounded product was not studied for this interaction. The compounding disclosure explains more.

Why does tirzepatide affect the pill?

Tirzepatide slows gastric emptying, the speed at which food and pills move from the stomach into the small intestine, where most absorption happens. A pill that sits in the stomach longer is absorbed later and reaches a lower peak (FDA Mounjaro label, 2025).

The label says this delay is largest after the first dose and diminishes over time. Acetaminophen shows the pattern. After a first tirzepatide dose, acetaminophen's peak concentration fell by 50% and arrived about an hour later. At week 4, there was no meaningful effect on the peak or its timing, and overall acetaminophen exposure was unchanged throughout.

This is not a liver-enzyme interaction. Many drug interactions run through CYP enzymes, liver proteins that break down many medicines. In laboratory studies, tirzepatide showed low potential to block or boost them. The issue is absorption timing, not how the body clears the hormones.

That is why attention centers on starting treatment and dose increases. A 2026 review for obstetrician-gynecologists flags those periods as when tirzepatide may reduce oral contraceptive exposure (Cureus, 2026). Claims that the effect stays at full strength all week, or that taking the pill at a different time of day solves it, are not supported by the label.

Stomach side effects are a separate concern. Nausea, diarrhea and vomiting are among the most common reactions, and most reports came during dose escalation and decreased over time (FDA Mounjaro label, 2025). As general context, vomiting or diarrhea can also interfere with pill absorption. Report them to your clinician, and see this guide to GLP-1 side effects and when to escalate.

What did the tirzepatide pill study actually measure?

It measured hormone blood levels from a combined birth control pill after a single tirzepatide dose timed to peak effect. Peak levels fell by more than half, total exposure fell by about a fifth, and the peak arrived hours later (FDA Mounjaro label, 2025).

The study (NCT04172987) was a single-center, open-label, two-period, fixed-sequence pharmacokinetic study in healthy female participants (ClinicalTrials.gov, NCT04172987). Pharmacokinetics describes how the body absorbs, distributes and clears a drug. The main question was how one tirzepatide injection changes levels of a combined pill containing ethinyl estradiol (an estrogen) and norgestimate (a progestin). Safety and tolerability were secondary.

Tirzepatide was given the day before hormone levels were measured, so measurement happened at peak tirzepatide exposure, when the effect on gastric emptying is greatest. In practice, that makes the result close to a worst-case snapshot.

Three terms explain the results:

• AUC (area under the curve): the total amount of hormone absorbed over time.
• Cmax: the highest blood level reached.
• tmax: how long it takes to reach that peak.

Norelgestromin is a compound the body makes from norgestimate. Time to peak was delayed by 2.5 to 4.5 hours. Summaries that stop at "about 20%" miss most of the story: peak levels fell much further and arrived later.

What the study did not measure:

• Pregnancies or ovulation. It was a pharmacokinetic study, not a contraceptive-efficacy study (ClinicalTrials.gov, NCT04172987).
• Repeated dosing. A 2024 pharmacist review notes the trial did not account for tachyphylaxis, the fading of a drug effect with repeated doses (JAPhA, 2024).
• Other pills. Only one combined pill was tested.
• Other populations. Participants were healthy volunteers.

Why do semaglutide studies look different?

Studies of semaglutide, another GLP-1 medicine, did not find a meaningful drop in birth control hormone levels. They used different designs, so they are not a head-to-head comparison with tirzepatide.

Steady state is the point, after repeated doses, where drug levels stay roughly stable. The 2015 authors concluded semaglutide is not expected to reduce the effectiveness of the combined pill they tested. They noted this matters for low-dose pills that depend on threshold concentrations.

A 2024 pharmacist literature review of 6 clinical trials found the one tirzepatide trial showed statistically significant changes in AUC, Cmax and Tmax, while the 5 studies of other GLP-1 receptor agonists showed no statistically or clinically significant effect (JAPhA, 2024). The authors attribute the difference to tirzepatide's rapid dose escalation and greater delay in gastric emptying. The 2026 review reaches the same conclusion for semaglutide, liraglutide, exenatide and dulaglutide (Cureus, 2026).

The honest caveat: the semaglutide studies enrolled postmenopausal women, and the injectable study measured at steady state. The tirzepatide study measured after one dose at peak effect. None of the sources here tested tirzepatide at steady state. For broader differences between the drugs, see semaglutide vs tirzepatide pathway differences.

Which birth control methods does the warning cover?

The warning covers oral hormonal contraceptives, meaning hormonal pills swallowed by mouth. The label says hormonal contraceptives not taken by mouth should not be affected, and barrier methods do not depend on absorption.

As general context, non-oral hormonal methods include implants, hormonal IUDs, injections, patches and rings, which skip the stomach. For emergency contraception, ask a pharmacist or clinician rather than assuming the routine-pill advice applies.

The partner question has a clear answer from the mechanism. A man taking tirzepatide does not change how his partner absorbs her pill. That is reasoning from the label, not a study finding: the effect is a stomach-timing effect, and a pill is absorbed through the stomach of the person who swallows it. The concern applies to someone taking both medicines.

Choosing a contraceptive method is a conversation with whoever manages your contraception. New Blue does not offer contraception.

Should pregnancy plans come up in a GLP-1 intake?

Yes. Human pregnancy data on tirzepatide are insufficient, animal studies raised concerns, and the Zepbound label says to stop the drug when pregnancy is recognized.

The Mounjaro label says available human data are insufficient to evaluate drug-related risk, and animal studies showed fetal growth reductions and abnormalities (FDA Mounjaro label, 2025). The Zepbound label says tirzepatide may cause fetal harm, weight loss offers no benefit in pregnancy, and a pregnancy exposure registry tracks outcomes (Zepbound label, DailyMed). The 2026 review's counseling approach stresses checking for oral contraceptive use and reassessing pregnancy intentions at follow-up (Cureus, 2026).

Product information outside the US is written by other regulators. Their wording differs, so this article sticks to the US labels. Some guides give a fixed stop-before-conceiving window and attribute it to the US label. This article gives no washout period. That decision belongs to your clinician.

What to tell the clinician at intake:

1. Your current contraceptive method, or your partner's if you are also asking about her.
2. Whether you are pregnant, could be, or plan to become pregnant.
3. Whether you are breastfeeding. The Mounjaro label describes only a single-dose lactation study.
4. Any stomach or bowel problems, including gastroparesis, a condition where the stomach empties very slowly.
5. Every oral medication you take.

Useful questions to ask back: Does my method fall under the label's oral contraceptive advice? What should I do if I vomit or have diarrhea? How would a pregnancy change the plan?

Who should not use tirzepatide at all?

Some people should not use tirzepatide regardless of contraception. A licensed clinician screens for this during intake review.

• Personal or family history of medullary thyroid carcinoma (MTC), a rare thyroid cancer, or multiple endocrine neoplasia type 2 (MEN 2), an inherited condition linked to it. The label lists both as contraindications under a boxed warning, because tirzepatide caused thyroid C-cell tumors in rats (FDA Mounjaro label, 2025).
• History of pancreatitis. The label warns of acute pancreatitis, including fatal cases, and says to stop if it is suspected. Excluding people with a pancreatitis history is a screening standard.
• Known serious hypersensitivity to tirzepatide, a label contraindication.
• Pregnancy.
• Severe gastroparesis, where the label says use is not recommended.

People with a personal or family history of MTC or MEN 2, or a history of pancreatitis, should not use these medications, and a licensed clinician screens for this. Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work. The GLP-1 eligibility checklist covers screening in more detail.

How access works through New Blue

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

1. You complete a structured intake covering your health history and medications, and you should include your contraception and pregnancy plans.
2. A licensed clinician reviews it asynchronously, without a scheduled visit. Some treatments or states may require a live visit. Consultation timing varies by clinician availability.
3. If appropriate, the clinician may prescribe compounded tirzepatide. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities and are not FDA-approved.
4. If prescribed, a licensed partner pharmacy ships the medication directly to you. Use follows your clinician's guidance and pharmacy instructions.

The Tirzepatide GLP-1 pathway ships to every state New Blue Health serves except North Dakota. Availability varies by state, so check state availability. Adults 21+ only. Not for emergencies. For current pricing, see the Tirzepatide GLP-1 pathway page. If treatment isn't appropriate, refunds follow our refund policy.

Frequently Asked Questions

Does tirzepatide make birth control pills less effective?

The FDA labels for Mounjaro and Zepbound say tirzepatide may reduce the efficacy of oral hormonal contraceptives because it delays gastric emptying. In the manufacturer's study, peak hormone levels fell 55% to 66% and total exposure fell 20% to 23% after a single dose timed to peak effect. The study measured blood levels, not pregnancies.

Do I have to stop my birth control pill if I start tirzepatide?

Not necessarily, but relying on the pill alone is not what the label advises. The label advises switching to a non-oral method or adding a barrier method after starting tirzepatide and after each dose increase. Decide with your clinician and whoever manages your contraception.

Does tirzepatide affect an IUD, implant, patch or ring?

The label says hormonal contraceptives that are not taken by mouth should not be affected. These methods skip the stomach, which is where the interaction happens. Copper IUDs and barrier methods do not depend on absorption at all.

I'm a man taking tirzepatide. Does it affect my partner's pill?

No, based on the mechanism. The interaction comes from slowed stomach emptying in the person taking tirzepatide, and a pill is absorbed through the stomach of whoever swallows it. This is reasoning from the label, not a study finding.

Does compounded tirzepatide carry the same birth control concern?

Compounded tirzepatide has the same active ingredient as Mounjaro and Zepbound, but compounded medications are not FDA-approved and were not the product studied. The brand labels are the best available reference. Your clinician applies them to your situation.

Does semaglutide have the same birth control concern?

Semaglutide studies did not show a meaningful drop in pill hormone levels. Those studies enrolled postmenopausal women, and the injectable study measured at steady state, while the tirzepatide study measured after one dose at peak effect. The results are not a head-to-head comparison.

Can I use tirzepatide while trying to get pregnant?

Raise it with your clinician before starting. Human pregnancy data are insufficient, animal studies showed fetal growth reductions and abnormalities, and the Zepbound label says to stop when pregnancy is recognized. Any timing decision belongs to your clinician.

Sources

1. MOUNJARO (tirzepatide) injection, for subcutaneous use: Full Prescribing Information and Medication Guide. U.S. Food and Drug Administration (Eli Lilly and Company label), 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
2. ZEPBOUND (tirzepatide) injection: Drug Label Information. DailyMed, U.S. National Library of Medicine, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
3. A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants (NCT04172987). ClinicalTrials.gov, 2019 and 2020 record versions. https://clinicaltrials.gov/study/NCT04172987
4. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. Journal of the American Pharmacists Association, 2024. https://doi.org/10.1016/j.japh.2023.10.037
5. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. The Journal of Clinical Pharmacology, 2015. https://doi.org/10.1002/jcph.443
6. Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. Clinical Pharmacokinetics, 2021. https://doi.org/10.1007/s40262-020-00976-x
7. Glucagon-Like Peptide-1 Receptor Agonists and Reproductive Health: A Narrative Review for Obstetrician-Gynecologists. Cureus, 2026. https://pubmed.ncbi.nlm.nih.gov/42544159/

Medical disclaimer: This article is educational and is not medical advice. Treatment decisions, including whether tirzepatide is appropriate and how it fits with your contraception, are made by a licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.